[Cancer Treatment-Induced Bone Loss(CTIBL)].
Cancer treatment-induced bone loss(CTIBL)is becoming a big problem with advancement of cancer treatment, increase of patients suffering from cancers and improvement of survival of these patients. Clinically, bone loss in patients with breast or prostate cancers taking hormone therapy is the most frequent problem. It has been reported that bisphosphonates and denosumab prevent the bone loss and fractures in a part of these patients. Some guidelines concerning CTIBL have been published by several foreign societies. In addition, bone loss and fractures in patients receiving hormone therapy are mentioned in the clinical practice guidelines by Japanese Breast Cancer Society and The Japanese Urological Association. However, there are some discrepancies in the evaluation and treatment of the patients in these guidelines. It is necessary to establish a management plan for patients with CTIBL in Japan in the future.